South Korea-Based UNDBIO Plans Morgantown, West Virginia, Insulin Manufacturing Complex
04/20/2023
The company secured a lease with West Virginia University and will work to receive FDA approval for the product.
"The mission of UNDBIO is to develop and produce state-of-the-art insulin in West Virginia,” UNDBIO Chairman Caleb Jun said. “Our products will save human lives and improve the quality of life for those afflicted with diabetes. We are excited to see West Virginia become a mecca for manufacturing highly advanced insulin to treat diabetic patients around the world."
UNDBIO is the only Korean pharmaceutical company to provide a complete Diabetes care Solution by offering high-quality affordable Insulin, Insulin Analogs to meet the unmet need of diabetes patients.
“I join the Governor in expressing my excitement for this announcement today,” Secretary of the West Virginia Department of Commerce Mitch Carmichael noted. “This announcement, this company, this investment, and the potential for so many jobs for our hardworking West Virginians makes for a very great day. Good things are on the horizon, this is just the beginning!”
Project Announcements
Wyandot Snacks Expands Marion, Ohio, Production Operations
08/29/2025
Trane Technologies Expands Fort Smith, Arkansas, Operations
08/29/2025
BioMADE Plans Boone, Iowa, Bioindustrial Manufacturing Operations
08/29/2025
Choice Fabricators Expands Rainbow City, Alabama, Production Operations
08/29/2025
Ranovus Expands Ottawa, Ontario, Semiconductor Operations
08/29/2025
Belgium-Based Stow Group Plans Gordon County, Georgia, Manufacturing Operations
08/28/2025
Most Read
-
Tariffs, Talent, and U.S. Expansion
Q3 2025
-
What We’re Getting Wrong About Gen Z’s Future in the Skilled Trades
Q3 2025
-
Data Center Demand Stabilizes Amid Changing Market Forces
Q3 2025
-
A New Course for U.S. Shipbuilding
Q3 2025
-
Optimizing Your Rail-Served Transportation Network: Strategy Before Steel
Q2 2025
-
In Focus: AI Is Changing Incentives Math
Q2 2025
-
Rewriting the Rules of Warehouse ROI
Q3 2025